ALMS

3.9608.55%
AB

Alan B. Colowick

Independent Director

Dr. Alan B. Colowick, MPH, MD, PhD, is Director of AltPep Corporation from February 2025. He served as an Independent Director at Maze Therapeutics, Inc. since December 2024 until February 2025. He is Director at ReCode Therapeutics, Inc. from June 2022. He is Director at XyloCor Therapeutics, Inc. since October 2018. He serves as an Independent Director of Alumis Inc. since January 2022. He served as Director at Human Longevity, Inc from July 25, 2016 to June 2019. He serves as Executive Chairman at Teon Therapeutics, Inc. since March 2021. Dr. Colowick served as Managing Director at Matrix Capital Management Company, L.P. since April 2021. He was a Managing Director on the Technology-Life Sciences team at Matrix Capital Management Company, LP and its affiliate, AyurMaya Capital Management Company, LP. He also serves on the BODs of Anumana and Teon Therapeutics, Inc. He had been an Independent Director at Harpoon Therapeutics, Inc. since March 2021 until June 22, 2023. He served as Independent Non-Executive Director at AC Immune SA since March 31, 2021 until June 23, 2023. He serves as the Director at Palleon Pharmaceuticals Inc. since 2022. He served as Executive Partner of Private Equity at Sofinnova Investment, Inc. since May 2017 until January 2021. Dr. Colowick served as the Independent Chairman of Principia Biopharma Inc. since April 2019 until September 28, 2020. He is a part of investment team at the firm. He focuses on clinical-stage product companies, particularly in oncology, rare diseases and other specialty therapeutic areas. He served as a Partner of Sofinnova Partners SAS since joining in 2017. Before joining Sofinnova, he held executive management and Board of Directors positions at numerous companies in the biotechnology sector. He serves on the board of InCarda Therapeutics Inc. since October 2017. Dr. Colowick served as Consultant of Threshold Pharmaceuticals, Inc. from October 14, 2006 to January 14, 2007 and served as its Chief Medical Officer from January 2005 to October 13, 2006. Prior to Gloucester Pharmaceuticals, he served as President of Oncology at Geron Corporation from October 2006 to February 2008. He served as Chief Executive Officer of Gloucester Pharmaceuticals, Inc. since January 2008 until its acquisition by Celgene in January 2010. Prior to Sofinnova, he was with Celgene Corporation from February 2010 to April 2017 serving most recently as Executive Vice President. He served as President of Europe, Middle East and Africa Region at Celgene International Sárl from 2012 to September 2014 served as Senior Vice President of Global Medical Affairs from 2010 to 2012. Dr. Colowick held various management positions with Amgen Inc., a biopharmaceutical company, including Vice President of European Medical Affairs. He served as Director of Personalis, Inc. since May 2019 until June 12, 2023. Dr. Colowick serves as Director at Solve Therapeutics. He serves as Director of Naryx Pharma, Inc. He serves as Chairman of Velos Biopharma Inc. He served as Director of Achaogen, Inc. since March 11, 2015 until July 31, 2017. He served as Member of Scientific Advisory Board at Threshold Pharmaceuticals, Inc. since October 14, 2006. He served as Independent Director Dimension of Therapeutics, Inc. since August 2015 until November 7, 2017. He served as Director of Gloucester Pharmaceuticals, Inc. since January 2008. He served as Director of Nora Therapeutics, Inc. He served as a Director since February 2017 and served as an Executive Chairman at Principia Biopharma Inc. since February 2017 until April 2019. He served as an Independent Director of ACELYRIN, Inc. since October 2021 until May 2025. He was a Clinical and Research Fellow with sub-specialty training in Hematology and Oncology form Brigham and Women’s Hospital, Harvard University and the Dana Farber Cancer Institute. He was chairman of the board of directors of VelosBio Inc. from September 2018 to December 2020. Dr. Colowick received his B.S. in Molecular Biology from the University of Colorado, M.D. from Stanford University School of Medicine and his M.P.H. from the Harvard School of Public Health.

Positions